StockNews.com Begins Coverage on Jaguar Health (NASDAQ:JAGX)

StockNews.com started coverage on shares of Jaguar Health (NASDAQ:JAGX – Get Rating) in a research note issued to investors on Thursday. The firm issued a hold rating on the biotechnology company’s stock.

Jaguar Health Stock Down 3.3 %

Jaguar Health stock traded down $0.03 during trading hours on Thursday, reaching $0.88. The stock had a trading volume of 1,476,848 shares, compared to its average volume of 1,732,788. The company has a market cap of $1.70 million, a price-to-earnings ratio of -0.01 and a beta of 1.83. The company has a debt-to-equity ratio of 5.56, a current ratio of 0.94 and a quick ratio of 0.69. The business’s 50 day moving average price is $2.40 and its 200-day moving average price is $0.93. Jaguar Health has a 52 week low of $0.86 and a 52 week high of $61.13.

Hedge Funds Weigh In On Jaguar Health

A number of large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its holdings in shares of Jaguar Health by 507.3% during the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock valued at $120,000 after acquiring an additional 141,796 shares in the last quarter. Citigroup Inc. acquired a new position in shares of Jaguar Health during the first quarter valued at about $34,000. Renaissance Technologies LLC acquired a new position in shares of Jaguar Health during the first quarter valued at about $1,079,000. Goldman Sachs Group Inc. increased its holdings in shares of Jaguar Health by 153.3% during the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 33,148 shares in the last quarter. Finally, Virtu Financial LLC increased its holdings in shares of Jaguar Health by 76.1% during the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock valued at $162,000 after acquiring an additional 99,073 shares in the last quarter. 11.77% of the stock is currently owned by institutional investors.

Jaguar Health Company Profile

(Get Rating)

Jaguar Health, Inc is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea.